How India Exports Clotrimazole to the World

In the United States, clotrimazole is approved for various formulations, including topical creams, lozenges, and otic solutions. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for clotrimazole products, indicating a competitive generic market. Notably, on September 26, 2025, the FDA approved an ANDA for Clotic (clotrimazole otic solution) by Carwin Pharmaceutical Associates. As of January 8, 2026, no generic version of Clotic is available in the U.S. market.

The presence of 712 active Indian exporters underscores the robust supply chain catering to the U.S. market. However, exporters must navigate the FDA's stringent regulatory pathways, including compliance with Current Good Manufacturing Practices (cGMP) and potential import alerts. Ensuring adherence to these regulations is crucial for maintaining market access and avoiding disruptions.

In the European Union and the United Kingdom, clotrimazole is subject to marketing authorization requirements overseen by the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Manufacturers must obtain approval for their products, demonstrating compliance with EU Good Manufacturing Practice (GMP) standards. For instance, in September 2011, the EMA recommended the suspension of the marketing authorization for Canazole (clotrimazole cream 1%) in Ireland due to concerns over its benefit-risk balance. (ema.europa.eu)

This highlights the importance of continuous monitoring and compliance with regulatory standards to maintain market authorization within the EU and UK.

Clotrimazole is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in treating fungal infections globally. The 24th edition of the list, published on September 5, 2025, reaffirms clotrimazole's essential status. (who.int)

Additionally, clotrimazole formulations are standardized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and efficacy across different markets.

In India, clotrimazole is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, clotrimazole is not listed under the Drug Price Control Order (DPCO), allowing manufacturers to set prices based on market dynamics.

For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products. Exporters must ensure compliance with these requirements to facilitate smooth international trade.

Clotrimazole's primary patents have expired, leading to a competitive generic market globally. This patent expiration has enabled numerous manufacturers to produce and export clotrimazole, contributing to the substantial number of active Indian exporters and the extensive global reach of the product.

In May 2025, the WHO's 25th Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines, reaffirming clotrimazole's inclusion. (who.int)

In September 2025, the FDA approved Carwin Pharmaceutical Associates' ANDA for Clotic (clotrimazole otic solution), expanding treatment options for otic fungal infections in the U.S. market.

In January 2026, the WHO published the 10th edition of the Model List of Essential Medicines for Children, continuing to list clotrimazole as an essential antifungal treatment for pediatric use. (who.int)

These developments reflect the ongoing recognition of clotrimazole's importance in global health and the dynamic regulatory landscape affecting its production and distribution.

India's pharmaceutical industry, while robust in manufacturing Active Pharmaceutical Ingredients (APIs) like Clotrimazole, remains significantly dependent on China for Key Starting Materials (KSMs). This reliance exposes the supply chain to vulnerabilities, as disruptions in Chinese production can lead to shortages and price volatility. For instance, in recent years, environmental regulations in China have led to the shutdown of several API manufacturers, causing supply disruptions and cost escalations for Indian pharmaceutical companies.

The COVID-19 pandemic further highlighted these vulnerabilities. Lockdowns and logistical challenges in China during 2020 and 2021 disrupted the supply of essential KSMs to India, impacting the production of various APIs, including Clotrimazole. This situation underscored the need for India to enhance its domestic production capabilities to mitigate risks associated with over-reliance on a single foreign source.

Our proprietary trade data indicates that the top five exporters of Clotrimazole from India account for 47.6% of the total export value, with CAPLIN POINT LABORATORIES LIMITED leading at a 13.0% share. This concentration suggests a moderate risk, as disruptions affecting these key suppliers could significantly impact the global supply chain.

To address such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in 2020, aiming to boost domestic manufacturing of APIs and reduce dependency on imports. By 2024, this initiative led to the establishment of new pharmaceutical plants focusing on essential APIs, marking a critical step toward self-sufficiency.

Global shipping routes, including the Red Sea and the Strait of Hormuz, have experienced disruptions due to geopolitical tensions and regional conflicts. Such disturbances can delay shipments of pharmaceutical products, including Clotrimazole, leading to supply chain uncertainties. Additionally, escalating trade tensions between major economies, notably the U.S. and China, have introduced further complexities in the pharmaceutical supply chain, potentially affecting the availability and pricing of APIs and KSMs.

Regulatory bodies like the FDA and EMA have periodically issued shortage alerts for various medications, highlighting the fragility of the pharmaceutical supply chain. While Clotrimazole has not been prominently featured in recent alerts, the interconnectedness of the supply chain means that disruptions in one area can have cascading effects on others.

• Diversify Supplier Base: Encourage the development of multiple domestic suppliers for Clotrimazole and its KSMs to reduce reliance on a limited number of exporters.

• Enhance Domestic Production: Leverage government initiatives like the PLI scheme to bolster local manufacturing capabilities for APIs and KSMs, thereby decreasing dependency on imports.

• Strengthen Supply Chain Resilience: Implement robust risk assessment frameworks to identify potential vulnerabilities and develop contingency plans for supply chain disruptions.

• Monitor Geopolitical Developments: Stay informed about international trade policies and geopolitical events that could impact shipping routes and raw material availability.

• Engage in Strategic Stockpiling: Maintain adequate reserves of critical APIs and KSMs to buffer against short-term supply disruptions.

RISK_LEVEL: MEDIUM